The importance of tumor angiogenesis in tumor biology is now widely accepted.
Hepatocellular carcinoma (HCC) is a highly vascular tumor, and angiogenesis is believed to …

A majority of patients with HCC present with advanced disease and are not candidates for
liver transplantation, surgical resection, or regional therapy. Systemic cytotoxic …

Hepatocellular carcinoma (HCC) is one of the most common and lethal malignant tumors
worldwide in the human population. Due to late diagnosis and/or advanced underlying liver …

Abstract Treatment of hepatocellular carcinoma has dramatically changed in the last years.
The better knowledge of the molecular mechanisms responsible of tumor initiation and …

Hepatocellular carcinoma (HCC) is the most common primary liver neoplasm and fourth
leading cause of cancer death worldwide. The survival for patients with advanced HCC is …

Thalidomide, which inhibits angiogenesis in certain tumor types, reduced extravasation of a
macromolecular contrast medium (MMCM) in a human breast cancer model as assayed by …

The prognosis for advanced hepatocellular carcinoma is poor and systemic therapy has
historically been of limited benefit. However, novel targeted agents offer promise in …

The emergence of chemotherapy in the 1950s has led to the availability of systemic
therapies for patients with hematologic malignancies and advanced solid tumors. These …

Hepatocellular carcinoma (HCC) is typically a hypervascular tumor and anti-angiogenesis
therapy may be effective for the treatment of HCC. Thalidomide has been shown to inhibit …

There has been no proven effective therapy in the setting of advanced HCC (hepatocellular
carcinoma) according to BCLC (Barcelona Clinic Liver Cancer). Targeted therapy opened a …